Ann Arbor-based Adeona Pharmaceuticals Inc. said Monday that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.
Cerenis Therapeutics, the pharma startup with offices in Toulouse, France and Portage, Tuesday announced the start of a Phase 2 clinical trial of its lead drug candidate, CER-001, in patients with acute coronary syndrome.
The Plymouth pharmaceutical developer Esperion Therapeutics Thursday announced that it has initiated a Phase 2 clinical study for ETC-1002, the company’s lead product candidate. ETC-1002 is a novel small molecule compound that has demonstrated preclinical […]
Ann Arbor-based Adeona Pharmaceuticals Inc., (Amex: AEN) Wednesday announced completion of 100 percent enrollment in Part 2 of its clinical study, “A Prospective, Randomized, Double Blind Trial of a Novel Oral Zinc Cysteine Preparation in […]
Stem cell skeptics have been asking for years, where are the cures? Well, stick around. Spectacular cures may be coming soon, and they have a University of Michigan connection.